Naresh Nebhinani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Naresh Nebhinani has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
Navratan Suthar
Department of Psychiatry, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India
12 shared publicationsDebasish Basu
Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India
9 shared publicationsVrinda Pareek
Department of Psychiatry, Government Medical College, Vadodara, Gujarat, India
6 shared publicationsAjay Wanchu
Consultant Rheumatologist, Adventist Medical Center, Portland, Oregon, United States
4 shared publicationsKartik Singhai
Department of Psychiatry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
4 shared publications- Pooja Patnaik Kuppili
Department of Psychiatry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
4 shared publications
Latest Publications
- 10 November 2026
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 126, 105215
Digital media use in schizophrenia and its associations with sleep quality and illness severity in an Indian cohort
- 10 November 2026
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 126, 105215
Digital media use in schizophrenia and its associations with sleep quality and illness severity in an Indian cohort
- Open Access
- 22 July 2026
- Published by SAGE Publications in Indian Journal of Psychological Medicine
- Vol. 48 (6) , 630-638
Association of Serum Adiponectin, Sleep Quality, and Health-promoting Lifestyle with Metabolic Syndrome in Patients with Schizophrenia
Background: Metabolic syndrome (MS) significantly contributes to premature mortality in schizophrenia, which is driven by multiple biological and behavioral factors. While individual risk factors are known, comprehensive studies examining the combined influence of biological markers (adiponectin) and behavioral factors (sleep, lifestyle) in the Indian context are limited. Methods: In this cross-sectional, observational study, 130 patients diagnosed with schizophrenia were assessed for MS using modified National Cholesterol Education Program Adult Treatment Panel III criteria. We evaluated symptom severity using the Brief Psychiatric Rating Scale, Sleep quality using the Pittsburgh Sleep Quality Index, and lifestyle behaviors using the Health-Promoting Lifestyle Profile-II. Blood samples were analyzed for serum adiponectin and metabolic profiles to diagnose MS. Results: The MS rate was 24.6%. Bivariate analyses revealed that patients with MS had a significantly longer time spent in exacerbation ( p = .03), a longer treatment duration ( p = .01), lower serum adiponectin levels ( p = .02), poorer sleep quality ( p = .001), and lower physical activity and nutritional habit scores ( p = .01). In the multivariable logistic regression model, poorer sleep quality (OR = 1.17, 95% CI = 1.06–1.30, p = .002) and a lower physical activity and nutritional habit score (OR = 0.92, 95% CI = 0.86–0.98, p = .01) emerged as significant predictors of MS. Conclusions: One-fourth of the patients with schizophrenia had MS in this cohort. Notably, modifiable behavioral factors—specifically sleep quality and lifestyle—were stronger predictors of metabolic risk. This signifies the vital need to integrate routine screening for cardiometabolic risk factors and to apply therapeutic strategies into the standard of care for schizophrenia.
- 22 July 2026
- Published by SAGE Publications in Indian Journal of Psychological Medicine
- Vol. 48 (6) , 630-638
Open AccessAssociation of Serum Adiponectin, Sleep Quality, and Health-promoting Lifestyle with Metabolic Syndrome in Patients with Schizophrenia
Background: Metabolic syndrome (MS) significantly contributes to premature mortality in schizophrenia, which is driven by multiple biological and behavioral factors. While individual risk factors are known, comprehensive studies examining the combined influence of biological markers (adiponectin) and behavioral factors (sleep, lifestyle) in the Indian context are limited. Methods: In this cross-sectional, observational study, 130 patients diagnosed with schizophrenia were assessed for MS using modified National Cholesterol Education Program Adult Treatment Panel III criteria. We evaluated symptom severity using the Brief Psychiatric Rating Scale, Sleep quality using the Pittsburgh Sleep Quality Index, and lifestyle behaviors using the Health-Promoting Lifestyle Profile-II. Blood samples were analyzed for serum adiponectin and metabolic profiles to diagnose MS. Results: The MS rate was 24.6%. Bivariate analyses revealed that patients with MS had a significantly longer time spent in exacerbation ( p = .03), a longer treatment duration ( p = .01), lower serum adiponectin levels ( p = .02), poorer sleep quality ( p = .001), and lower physical activity and nutritional habit scores ( p = .01). In the multivariable logistic regression model, poorer sleep quality (OR = 1.17, 95% CI = 1.06–1.30, p = .002) and a lower physical activity and nutritional habit score (OR = 0.92, 95% CI = 0.86–0.98, p = .01) emerged as significant predictors of MS. Conclusions: One-fourth of the patients with schizophrenia had MS in this cohort. Notably, modifiable behavioral factors—specifically sleep quality and lifestyle—were stronger predictors of metabolic risk. This signifies the vital need to integrate routine screening for cardiometabolic risk factors and to apply therapeutic strategies into the standard of care for schizophrenia.
- Open Access
- 19 May 2026
- Published by Wolters Kluwer Health in Indian Journal of Psychiatry
- Vol. 68 (5) , 442-448
Internalized stigma in patients with severe mental illness (SMI): A cross-sectional study from Northwestern India
Background: Stigma is prevalent among patients with severe mental disorders; however, there is a lack of comprehensive evaluation that accounts for the contextual heterogeneity across India. Aim: This study aimed to examine the extent of stigma and associated factors in individuals with severe mental illnesses. Methods: The research involved a sample of 200 patients in clinical remission, who had been diagnosed with schizophrenia (N = 64), bipolar disorder (BD) (N = 68), and recurrent depressive disorder (RDD) (N = 68). The participants were assessed using the Internalized Stigma of Mental Illness Scale and Participation scale. Results: Patients suffering from schizophrenia and BD reported significantly more stigma in comparison to those with RDD. However, the levels of stigma between schizophrenia and BD did not differ markedly. Schizophrenia patients showed greater social withdrawal and resistance to stigma, while those with bipolar disorder were more likely to endorse stereotypes and report experiences of discrimination. No significant association was found between demographic factors and stigma among the schizophrenia and bipolar groups. Conversely, in the RDD group, older age was linked to lower levels of stigma across various domains. Conclusions: Individuals with schizophrenia and BD face greater internalized stigma than those with RDD, highlighting distinct domain-specific patterns and differences in the extent of stigma experienced across severe mental disorders.
- 19 May 2026
- Published by Wolters Kluwer Health in Indian Journal of Psychiatry
- Vol. 68 (5) , 442-448
Open AccessInternalized stigma in patients with severe mental illness (SMI): A cross-sectional study from Northwestern India
Background: Stigma is prevalent among patients with severe mental disorders; however, there is a lack of comprehensive evaluation that accounts for the contextual heterogeneity across India. Aim: This study aimed to examine the extent of stigma and associated factors in individuals with severe mental illnesses. Methods: The research involved a sample of 200 patients in clinical remission, who had been diagnosed with schizophrenia (N = 64), bipolar disorder (BD) (N = 68), and recurrent depressive disorder (RDD) (N = 68). The participants were assessed using the Internalized Stigma of Mental Illness Scale and Participation scale. Results: Patients suffering from schizophrenia and BD reported significantly more stigma in comparison to those with RDD. However, the levels of stigma between schizophrenia and BD did not differ markedly. Schizophrenia patients showed greater social withdrawal and resistance to stigma, while those with bipolar disorder were more likely to endorse stereotypes and report experiences of discrimination. No significant association was found between demographic factors and stigma among the schizophrenia and bipolar groups. Conversely, in the RDD group, older age was linked to lower levels of stigma across various domains. Conclusions: Individuals with schizophrenia and BD face greater internalized stigma than those with RDD, highlighting distinct domain-specific patterns and differences in the extent of stigma experienced across severe mental disorders.
- 17 February 2026
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 118, 104897
Development and psychometric evaluation of an abbreviated form of the revised suicide crisis inventory (A-SCI)-2 in major depression: A multicentric investigation
- 17 February 2026
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 118, 104897
Development and psychometric evaluation of an abbreviated form of the revised suicide crisis inventory (A-SCI)-2 in major depression: A multicentric investigation
- 3 February 2026
- Published by Springer Nature
- p. 279-299
Disaster and Disability
- Open Access
- 23 January 2026
- Published by SAGE Publications in Indian Journal of Psychological Medicine
Reply to the Comments on “Sexual Dysfunction and Its Correlates Among Men Dependent on Natural Opium”
- 23 January 2026
- Published by SAGE Publications in Indian Journal of Psychological Medicine
Open AccessReply to the Comments on “Sexual Dysfunction and Its Correlates Among Men Dependent on Natural Opium”
- 9 November 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 134, 1-5
Brivaracetam vs. Oxcarbazepine in childhood self-limited focal epilepsies (BRAVO-SeLFEs): A pilot randomized controlled trial
- 9 November 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 134, 1-5
Brivaracetam vs. Oxcarbazepine in childhood self-limited focal epilepsies (BRAVO-SeLFEs): A pilot randomized controlled trial
- Open Access
- 30 July 2025
- Published by SAGE Publications in Indian Journal of Psychological Medicine
Feedback Framework in Psychiatry Residency Training: A Cross-sectional Survey Amongst Psychiatry Post-graduate Residents of India
Background: Feedback has proven crucial in various training systems, especially medical training. However, data regarding the effectiveness of a feedback framework in psychiatry post-graduate (PG) training is limited. Hence, we undertook this survey to assess the essential components of a feedback mechanism in psychiatry PG training in India. Methods: This is a cross-sectional survey in which a questionnaire was circulated online to residents pursuing psychiatry training across various medical colleges, institutions, and hospitals in India. The questionnaire aimed to cover various aspects of a feedback program for psychiatry PG training. The target audience was kept as residents since they are the main benefactors of an effective feedback system. Results: We received responses from 262 residents from 84 departments nationwide. The majority ( n = 248, 94.7%) believed that a feedback system is necessary in psychiatry residency. Most believe feedback about outpatient and inpatient clinical performance and patient management skills is highly valuable. Real-time feedback was reported to be helpful, and faculty, followed by senior residents, became the most desired sources of feedback. Conclusions: The survey highlights that residents strongly need a feedback mechanism during psychiatry residency. Implementing a feedback program and constantly evaluating its effectiveness could go a long way in improving psychiatry training outcomes in India.
- 30 July 2025
- Published by SAGE Publications in Indian Journal of Psychological Medicine
Open AccessFeedback Framework in Psychiatry Residency Training: A Cross-sectional Survey Amongst Psychiatry Post-graduate Residents of India
Background: Feedback has proven crucial in various training systems, especially medical training. However, data regarding the effectiveness of a feedback framework in psychiatry post-graduate (PG) training is limited. Hence, we undertook this survey to assess the essential components of a feedback mechanism in psychiatry PG training in India. Methods: This is a cross-sectional survey in which a questionnaire was circulated online to residents pursuing psychiatry training across various medical colleges, institutions, and hospitals in India. The questionnaire aimed to cover various aspects of a feedback program for psychiatry PG training. The target audience was kept as residents since they are the main benefactors of an effective feedback system. Results: We received responses from 262 residents from 84 departments nationwide. The majority ( n = 248, 94.7%) believed that a feedback system is necessary in psychiatry residency. Most believe feedback about outpatient and inpatient clinical performance and patient management skills is highly valuable. Real-time feedback was reported to be helpful, and faculty, followed by senior residents, became the most desired sources of feedback. Conclusions: The survey highlights that residents strongly need a feedback mechanism during psychiatry residency. Implementing a feedback program and constantly evaluating its effectiveness could go a long way in improving psychiatry training outcomes in India.
- 21 June 2024
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 44 (4) , 434-436
Atomoxetine Associated Activation Syndrome in Adolescent Patients With ADHD
- 21 June 2024
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 44 (4) , 434-436
Atomoxetine Associated Activation Syndrome in Adolescent Patients With ADHD
- 14 March 2024
- Published by Springer Nature
- p. 49-60
Course and Outcome of Dhat Syndrome